Andrew Midler founded Savitr Capital LLC in 2008, a privately owned investment company which invests in emerging and innovative technology driven companies. Savitr Capital is currently invested in a portfolio of innovation leaders focused in health care and industrial manufacturing. Mr. Midler currently serves on the board of directors of Druggability Technologies, Glytec Systems, CellMDX, Emerald Bio Agriculture, Ancora Heart, BioIQ, and Vascular Therapies. In the majority of these Savitr is a large shareholder and participates at the Board level.
Previously, Mr. Midler founded Standard Pacific Capital in 1995. The investment management firm launched with $75m of assets and grew to over $5 billion and a team of 100 people by 2005. Mr. Midler managed the firm’s Global Long/Short Equity Fund until 2005, Standard Pacific’s flagship product. He also supervised the firm’s Credit Opportunities, Commodity, Quantitative, and Japan Long/Short Equity strategies. He served as the firm’s CIO and CEO from 1995 until December 2007. In December of 2007, he sold his majority ownership interest in the firm. Prior to founding Standard Pacific, he served as the director of equity portfolio management at CS First Boston, a global institutional money management firm. Previously, he managed a significant portion of the global hedge fund Odyssey Partners. From 1986 through 1993, he worked at Fidelity Investments and his tenure included assignments as portfolio manager of the Fidelity Convertible Securities Fund, Fidelity Equity Income II Fund, and Fidelity Growth & Income Fund. He holds an MBA from Harvard Business School and MA and BA degrees in Political Science from Stanford University.